Clinical Trial DRUG MDV3100-11
- A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer
- Principal Investigator
- William Gradishar
- Status: CLOSED
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG MDV3100-11
- The study will help doctors decide if enzalutamide may be a potential treatment for women with breast cancer, including triple-negative breast cancer, which expresses the androgen receptor. This study is also being done to test the safety and tolerability of enzalutamide, meaning, how taking enzalutamide may affect a patient's health or make her feel.
- Enzalutamide is known as an androgen receptor inhibitor, which means that it blocks activity of the hormone testosterone. In breast cancer, inhibiting the androgen receptor may possibly slow or stop tumor growth. This is the second study using enzalutamide in the treatment of women with breast cancer.
Some of the eligibility criteria include:
- Participants must be women at least 18 years of age.
- Participants must have advanced androgen receptor-positive, triple-negative breast cancer.
- Description of Treatment
- Study participants will take enzalutamide once per day by mouth during the treatment period, which starts on study Day 1. The treatment period will end when the doctor decides that the participant should stop taking enzalutamide, the participants start a new cancer therapy or clinical trial, or if the participant wants to stop taking enzalutamide.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by William Gradishar
- A Phase 2, Randomized, Open-Label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast Cancer
- A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)
- A Study Of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients with Her2+ Metastatic Breast Cancer Who Have Received Two or More Prior Her2-Directed Regimens in the Metastatic Setting (NALA)
- A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes,Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
last updated: 01-Jul-15 04:07 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.